Timothy Pigot - Mar 7, 2023 Form 3 Insider Report for Aerovate Therapeutics, Inc. (AVTE)

Role
Chief Commercial Officer
Signature
/s/ George A. Eldridge, Attorney-in-Fact
Stock symbol
AVTE
Transactions as of
Mar 7, 2023
Transactions value $
$0
Form type
3
Date filed
3/8/2023, 05:01 PM
Next filing
Jan 24, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding AVTE Common Stock 1.96K Mar 7, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding AVTE Stock Option (Right to Buy) Mar 7, 2023 Common Stock 77K $14.00 Direct F2
holding AVTE Stock Option (Right to Buy) Mar 7, 2023 Common Stock 30K $10.61 Direct F3
holding AVTE Stock Option (Right to Buy) Mar 7, 2023 Common Stock 74K $25.57 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 1,960 shares purchased under the Issuer's 2021 Employee Stock Purchase Plan on October 31, 2022 in a transaction that is exempt under Rule 16b-3(c) and 16b-3(d).
F2 25% of this option vested and became exercisable on June 14, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter.
F3 This option shall vest in 48 substantially equal monthly installments, with the first installment vested on January 14, 2022.
F4 This option shall vest in 48 substantially equal monthly installments, with the first installment vested on March 7, 2023.